Kornimate/medical-research-clean huggingface dataset:
pulmonary function after hyperbaric oxygen therapy

Conditions: Oxygen Toxicity

Summary: patients receiving hyperbaric oxygen therapy (hbot) for any indication at the hyperbaric medicine unit (university health network, toronto, on, canada) from 2016-2021 were recruited to this prospective cohort study. while receiving hbot (at 2.0-2.4 ata, with 1-3 "air breaks", with specific treatment details determined on a case-by-case basis and directed by the clinical team), enrolled patients underwent pulmonary function testing prior to hbot treatment and serially after each 20 completed treatment cycles.

patients receiving hyperbaric oxygen therapy (hbot) at the hyperbaric medicine unit (university health network, toronto, on, canada) from 2016-2021 were recruited with informed consent to this prospective cohort study. all included patients underwent hbot in one of three monoplace chambers (sechrist 3600h and sechrist 4100h, sechrist industries inc., anaheim, ca, usa; pah-s1-3200, pan-america hyperbarics inc., plano, tx, usa) or via a plastic hood in a multiplace chamber (hyperbaric system, fink engineering pty-ltd, warana, australia). hbot was performed with 100% oxygen at 2.0-2.4 ata, with 1-3 "air breaks", typically at 5 sessions per week, with limited variation depending on the treatment indication and patient/clinician decision. study participants completed pulmonary function testing (pfts) at several intervals during their hbot treatment: prior to the first hbot session, and serially after every 20 subsequent treatments. pfts were performed using a koko trek usb spirometer software and pneumotachometer (koko, usa), with the assistance of a trained technician and in accordance with industry norms. retrospectively, pft data was collected from all enrolled patients' electronic and paper medical charts. this data included anonymized patient demographics, as well as percentage of predicted forced expiratory volume in one second (fev1), forced vital capacity (fvc), and forced mid-expiratory flow rates (fef25-75). pft values underwent statistical analysis to identify potential effects of hbot on pulmonary function.

Eligibility criteria:
inclusion criteria: * patients scheduled to receive at least ten cycles of hbot (for any indication) exclusion criteria: * inability to provide informed consent

Keywords: hyperbaric oxygen therapy pulmonary function hyperoxia
comparison of the decannulation protocol with suctioning and capping in severe acquired brain injury patients

Conditions: Tracheostomy Decannulation; Acquired Brain Injury

Summary: single-center randomized trail focused on tracheostomized patients with severe acquired brain injury , comparing two different decannulation protocols: 1. an assessment of readiness for decannulation that was based on suctioning frequency 2. an assessment that was based on tracheostomy capping


Eligibility criteria:
inclusion criteria: * within three months of onset * age≥18 years old * gcs≥8 * clinical stability( defined as the absence of fever, sepsis, or active infection and hemodynamic stability) * without massive pooling or silent aspiration of saliva, more than one efficient swallow per minute, adequate cough reflex were tested by gently touching the aryepiglottic region with the tip of the endoscope. * passing a tracheostomy-tube de-cuff test(de-cuff the tube for 3 days without pulmonary complications. * without significant airway stenosis. exclusion criteria: * patients with pending diagnostic or therapeutic procedures and were considered by the clinicians to be at risk for neurologic deterioration * medical history of severe respiratory system or heart disease * neuromuscular disease other than icu-acquired weakness, or tracheostomy for airway control * don't get informed consent from patient or guardian

Keywords: tracheostomy decannulation without capping airway patency assessment
the effect of vitamin a on atherosclerosis

Conditions: Atherosclerosis

Summary: the aim of this study is the comparison between the effects of supplementation with 25000 iu preformed vitamin a (retinyl palmitate) or placebo for 4 months on gene expression of t cd4+ lymphocyte in atherosclerotic patients(documented with angiography).

atherosclerosis, the leading cause of death and disability in the world, is considered an inflammatory disease with a complex etiology. the immune system has a prominent role in the formation, development and destabilization of atherosclerotic plaques. a whole range of identified cytokines have been shown to play a part in atherogenesis, some with proatherogenic properties while others having antiatherogenic properties. with increasing evidence for the significant role of inflammation and the cytokines involved together with the th1/th2 imbalance in atherosclerosis and its progression to coronary artery diseases (cads), the control of cytokine production may become potential therapeutic targets and modulation of the th1/th2 balance may provide a new pharmacological tool to treat this disease. vitamin a (va) or va-like analogs known as retinoids, are potent hormonal modifiers of type 1 or type 2 responses but a definitive description of their mechanism(s) of action is lacking. high level dietary vitamin a enhances th2 cytokine production and iga responses, and is likely to decrease th1 cytokine production. retinoic acid inhibits il 12 production in activated macrophages, and ra pretreatment of macrophages reduces ifnγ production and increases il4 production in antigen primed cd4 t cells. supplemental treatment with vitamin a or retinoic acid (ra) decreases ifnγ and increases il5, il10, and il4 production. thus, vitamin a deficiency biases the immune response in a th1 direction, whereas high level dietary vitamin a may bias the response in a th2 direction.

Eligibility criteria:
inclusion criteria: • the criteria for enrollment of the patients and control subjects is consecutive patients of both sexes referred to the division of cardiology of the one of the hospitals of tehran university of medical sciences for coronary angiography for investigation of chest pain and/or suspected cad. exclusion criteria: * patients who have diseases which affect on th1/th2 balance such as asthma, active viral infections, and autoimmune diseases, or * patients who have allergy to vitamin a compounds, or * patients who have used vitamin supplements in last 3 months.

Keywords: atherosclerosis coronary artery disease vitamin a cd4-positive t-lymphocytes gene expression
improving infant nutrition in southern ethiopia

Conditions: Nutrition Disorders

Summary: this cluster randomized controlled trial will test the effect of the promotion of vitamin a-rich orange flesh sweet potato (ofsp) production and nutrition education on vitamin a and energy intake, including any added value of the healthy baby toolkit.

child stunting and vitamin a deficiency are persistent public health problems in ethiopia. quality diets for better health (qdbh) is a european union-funded project led by the international potato center (cip), in partnership with people in need (pin), emory university and with support of governmental organizations and local universities. the 54 month-project strives to improve diet quality, primarily of women and young children, through the promotion of vitamin a-rich orange flesh sweetpotato (ofsp) production and nutrition education in 41 kebeles (communities) in snnpr, reaching an estimated 15000 households. in addition, households in a subset of communities will receive a healthy baby toolkit, consisting of a marked bowl, slotted spoon, and illustrated counseling card. the healthy baby toolkit is designed to promote optimal complementary feeding practices of infants and young children 6 to 23 months, namely meal volume, meal frequency, and meal thickness. as part of this project, emory university will conduct a longitudinal, cluster randomized controlled trial in 20 kebeles to test the effect of the project on vitamin a and energy intake, including any added value of the healthy baby toolkit.

Eligibility criteria:
inclusion criteria: 1. participation in a healthy living club (only a criteria for those in partial or full intervention arms) 2. infant aged birth to 5 months 3. primary caregiver and head of household (if different from primary caregiver) available and provides consent for survey exclusion criteria: 1. serious health problem (for example, hiv/aids or congenital defect)

Keywords: nutrition women young children ethiopia vitamin a orange flesh sweet potato
a study to assess the effect of my happy flo on alleviating period symptoms and heavy flows.

Conditions: Menstrual Cramps; Women's Health; Fatigue

Summary: this clinical study aims to evaluate the effectiveness of my happy flo, a dietary supplement, in alleviating period symptoms and heavy menstrual flows. the study involves 40 participants, who will take the supplement daily for three menstrual cycles. primary outcomes, such as the severity of heavy flows, prolonged periods, cramps, mood, energy levels, cycle regulation, and fatigue, will be measured using validated questionnaires completed after each menstrual cycle. secondary outcomes, including vitamin d and iron levels, will be assessed through blood tests at the beginning and end of the study period.


Eligibility criteria:
inclusion criteria: * female, aged 18 or over * experiencing heavy period flows * two or more self-reported symptoms (prolonged periods, cramps, poor mood, fatigue, irregular cycle) * signs of potential anemia or iron deficiency * no known allergies to the product ingredients * willing to comply with study requirements and limit caffeine intake * generally healthy - do not live with any uncontrolled chronic disease exclusion criteria: * anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders * a diagnosis of sports anemia within the previous 6 months * anyone with known severe allergic reactions that require an epi-pen * women who are pregnant, breastfeeding, or trying to conceive * anyone unwilling to follow the study protocol * anyone who has undergone any surgeries or invasive treatments (such as immunotherapy, chemotherapy, radiation, or biological cancer) in the last 30 days or has any planned for the next 12 weeks * anyone with a history of substance abuse * anyone currently participating or planning to participate in a research study * anyone taking prescription anticonvulsants (anti-seizure medications) * anyone taking prescription anticoagulant medications (blood thinners) * anyone taking any hormone-modulating medications (e.g., hormonal birth control, hormone replacement therapy, testosterone, tamoxifen, thyroid medications, etc.) * history of hysterectomy, oophorectomy, or other surgery to the reproductive organs * history of gynecologic cancer, such as cervical, ovarian, uterine, vaginal, or vulvar cancer * currently experiencing menopausal or perimenopausal symptoms * changes or cessation of hormonal birth control in the last three months * active or abnormal uterine/vaginal bleeding * resides in ri, ny, nj, or az

Keywords: menstrual health period symptoms
the regression pattern of primary lesions in lung cancer after definitive radiotherapy

Conditions: Lung Cancer

Summary: definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. the recommended dose for definitive radiotherapy is 60-70gy, and the optimal dose is still uncertain. residual lesion after radiotherapy is a risk factor for recurrence. high doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. the regression pattern of primary lesions in lung caner after radiotherapy has not been clarified. this study intends to retrospectively collect clinical data of lung cancer patients with definitive radiotherapy, and explore the pattern of tumor regression after radiotherapy. it will help optimize the radiotherapy plan for lung cancer, so as to improve the efficacy and prognosis.

this study intends to retrospectively screen and include participants according to inclusion and exclusion criteria, and collect the clinical data of participants by previous medical records. imaging tools will be used to quantify changes in the spatial location, diameter and volume of target lesions to evaluate tumor regression rate and radiotherapy efficacy, and to explore tumor regression pattern and establish model. in addition, the relationship between tumor regression rate, incidence of adverse radiation events, prognosis and related factors will be analysed.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old; 2. stage ii-iii lung cancer with a clear pathological diagnosis report or medical record, not undergoing surgery before radiotherapy; 3. the primary lung lesion received definitive radiotherapy (defined as conventional fractionation radiotherapy with dose ≥50gy, stereotactic radiotherapy with biologically effective dose ≥100gy); 4. the target lesion of the lung receiving radiotherapy can be measured; 5. imaging data can be obtained before and after radiotherapy; 6. complete radiotherapy as planned, or the actual received dose has reached the defined definitive dose. exclusion criteria： 1. before radiotherapy, the primary lesion of the lung had received local treatment such as surgery or ablative treatment; 2. the radiotherapy plan was not completed, and the actual dose received did not reach the definitive dose (defined as conventional fractionation radiotherapy with dose \<50gy, stereotactic radiotherapy with biologically effective dose \<100gy)； 3. required imaging data cannot be obtained; 4. other conditions considered by the investigator to be inappropriate for enrollment.

Keywords: lung cancer radiotherapy
immune profile of acute myeloid leukemia patients receiving azacitidine plus venetoclax induction chemotherapy

Conditions: Acute Myeloid Leukemia

Summary: this study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (aml). studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.

primary objective: i. to evaluate immune profile of aml patients receiving venetoclax plus azacitidine induction chemotherapy. secondary objective: i. to determine clinical responses based on immune infiltrated vs immune depleted subtypes of aml receiving azacitidine and venetoclax chemotherapy. outline: this is an observational study. patients undergo blood sample collection and bone marrow aspirate on study. patients' medical records are reviewed.

Eligibility criteria:
inclusion criteria: * adults \> 18 yrs of age with diagnosis of acute myeloid leukemia who received azacitidine plus venetoclax chemotherapy * treatment naive adult acute myeloid leukemia patients exclusion criteria: * acute myeloid leukemia patients receiving azacitidine and venetoclax as salvage therapy will be excluded * patients who are pregnant or breast-feeding
regional cryotherapy in preventing paclitaxel induced peripheral neuropathy in breast cancer patients

Conditions: Breast Cancer

Summary: the trial will be preceded by a pilot phase study in 5 patients. this will then be followed by the randomized 1:1 phase ii trial testing the utility of regional cryotherapy in preventing or reducing paclitaxel-induced peripheral neuropathy compared to no treatment. it is hypothesized that cryotherapy causes regional blood vessel constriction and decreases the paclitaxel exposure to the distal epithelial nerve fibres, thus resulting in decreased nerve damage.


Eligibility criteria:
inclusion criteria: 1. provision of written informed consent prior to any study specific procedures. 2. age ≥ 21 years old 3. patients with histologically confirmed early or locally advanced breast cancer 4. must be receiving 12x weekly sessions of paclitaxel as part of their adjuvant or neo-adjuvant chemotherapy 5. must have routine chemotherapy lab investigations as per institutional practice 6. concurrent use of trastuzumab and/or pertuzumab for cerbb-2 positive patients as per institutional practice is allowed 7. patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations. exclusion criteria: 1. patients diagnosed with pre-existing or history of peripheral neuropathy (regardless of cause) 2. patients with history of raynaud's disease 3. prior use of taxane-based chemotherapy 4. concurrent use of other neuro-toxic chemotherapy with paclitaxel 5. patients who have had any axillary clearance surgery and without a central venous access device for chemotherapy administration 6. patients with any severe and/or uncontrolled medical condition that would, in the investigator's judgment, contraindicate patient participation in the clinical study.

Keywords: paclitaxel neuropathy
prenatal examination of deletion 22q11 syndrome : thymic dysgenesis thymi study

Conditions: 22q11 Deletion Syndrome Di George Syndrome

Summary: 22q11.2 microdeletion seems the prenatally under-diagnosed . indeed , there is a mismatch between the series on the heart rate of 22q11.2 antenatal 84% against 30% in the adult series despite a perinatal mortality of 16% suggesting opportunities for improvement in the prenatal diagnosis of fetus with a microdeletion 22q11.2 , especially without heart disease


Eligibility criteria:
inclusion criteria: * all prenatal diagnosis with fish or cgh array of a fetal 22q11 deletion syndrome during the inclusion period. * the pregnancy follow-up should be done one of the 44 french fetal medicine unit. * sonographic picture of 3 vessels slides should be communicated for independent review. exclusion criteria: * no sonographic picture available
characterization of the genetic profile of type 2 endometrial carcinoma in martinique

Conditions: Endometrial Neoplasms

Summary: in martinique, about 33 new cases are diagnosed per year, with a high incidence rate of type 2 endometrial carcinoma which has a poor prognosis with few therapeutic options. although targeted therapies are used in many types of cancer, they are still possible a minority of patients. in current practice, endometrial cancers do not benefit these therapies. characterization of the molecular mechanisms involved in the genesis of type 2 endometrial carcinoma could help to identify biomarkers predictive of a response to targeted therapies. we propose to identify the genetic profile of type 2 endometrial carcinomas in martinique.

type 2 endometrial carcinomas are often diagnosed at advanced stages, with an high risk of metastatic recurrence and death even when diagnosed at early stages. they also have few therapeutic options. the characterize the mutations responsible of cancer development has led to develope "precision medicine" that targets "actionable genes" by a drug. this concept of actionable mutation refers to a change in the dna molecule that can predict the response to a drug defined as targeted therapy. although targeted therapies are used in many types of cancer, they still target a minority of patients. some tumor sites still do not benefit from these treatments. specifically, type 2 endometrial cancers that have poor prognosis with few therapeutic options. the characterization of molecular mechanisms, by next generation sequencing (ngs), involved in the carcinogenesis of endometrial cancers, particularly type 2 cancers, should allow the identification of predictive biomarkers for response to certain targeted therapies.

Eligibility criteria:
inclusion criteria: * major subject living in martinique with the following characteristics : * patients with type 2 endometrial cancer, with anatomopathological confirmation * affiliate or beneficiary of french social security. * free, informed with a written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any research required by the research). exclusion criteria: * type 1 adenocarcinoma * patients not affiliated to french social security * refusal to participate.

Keywords: endometrial carcinoma
efficacy of buffered lidocaine in patients with facial swelling

Conditions: Orofacial Swelling

Summary: the purpose of this study is to determine the clinical efficacy of a buffered 4% lidocaine solution for incision and drainage. ninety patients will be examined clinically to determine a diagnosis of cellulitis or fluctuance. the diagnosis will be confirmed by incision and drainage. patients will receive either 3.6 ml 4% lidocaine with 1:100,000 epinephrine or 3.6 ml 4% lidocaine with 1:100,000 epinephrine buffered with 8.4% sodium bicarbonate. patients will rate pain prior to and throughout the procedure.

incision and drainage of swellings is painful and anesthetic failure is common. one reason may be related to the lowered ph of inflamed tissue reducing the amount of the base form of anesthetic. a buffered anesthetic solution may result in more effective anesthesia than a non-buffered solution.

Eligibility criteria:
inclusion criteria: * 18 years or older * in good health (asa classification i or ii) * able to give informed consent * necrotic tooth with associated facial swelling exclusion criteria: * allergies to local anesthetics or sulfites * history of significant medical problems (asa classification iii or greater) * pregnancy * inability to give informed consent
organ preservation in the multispeciality therapy of stage ii-iv locally advanced head and neck cancer

Conditions: Head and Neck Cancer

Summary: this protocol was opened to collect long term survival information on subjects enrolled in a previous study which evaluated the impact of neoadjuvant chemotherapy and concomitant chemoradiotherapy with organ preserving optional surgery on overall survival, time to progression, pattern of disease recurrence in patient with locally advanced head and neck cancer. the last surviving subject was last treated in 1989, and was lost to follow up in 2010.


Eligibility criteria:
eligibility criteria: eligibility criteria: subjects previously enrolled in a treatment protocol for locally advanced head and neck cancer who met the following criteria: 1. patients with stage iv carcinoma of the nasal or oral cavity, nasopharynx pharynx, larynx, paranasal sinuses, cervical esophagus, or hypopharynx are eligible. patients with stage iii carcinoma of the nasopharynx, base of tongue and hypopharynx are also eligible. therapy is given with curative intent. prior to entry in the study the resectability and standard treatment options for each patient will be determined during a joint evaluation by a team composed of an attending surgeon, a radiation oncologist and a medical oncologist. in addition the timing and feasibility of surgery will be determined in each patient prior to initiation of therapy. the unequivocal demonstration of distant metastasis confers in eligibility. 2. measurable disease is not required, but all disease will be carefully evaluated. 3. patients must have a histologically or cytologically confirmed diagnosis of squamous cell carcinoma, mucoepidermoid carcinoma or lymphoepithelioma. 4. patients must have not received prior chemotherapy or radiotherapy. 5. patients must have performance status of \>60% 6. patients must have a wbc count of \>3.5, an anc count \>1500 and a platlet count of \>100,000. 7. the serum creatinine must be equal to or less than 1.5 m/dlor the calculated creatinine clearance must exceed 50cc/min. 8. patient must be free of significant infection or other severe complicating medical illness. 9. pregnancy will constitute an absolute contraindication to entrance on this protocol.

Keywords: head neck cancer advanced oral cavity lip larynx